Springworks Therapeutics Inc   (SWTX)
Other Ticker:  
Price: $52.0700 $3.59 7.405%
Day's High: $52.884 Week Perf: 5.79 %
Day's Low: $ 48.03 30 Day Perf: 22.84 %
Volume (M): 2,009 52 Wk High: $ 53.78
Volume (M$): $ 104,593 52 Wk Avg: $29.48
Open: $48.14 52 Wk Low: $18.00

 Market Capitalization (Millions $) 3,287
 Shares Outstanding (Millions) 63
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -325
 Cash Flow (TTM) (Millions $) 109
 Capital Exp. (TTM) (Millions $) 10

Springworks Therapeutics Inc
Springworks Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with severe rare diseases and cancer. The company's primary goal is to address unmet medical needs and improve patients' lives by advancing its robust pipeline of therapeutic candidates. Springworks Therapeutics utilizes a strategic approach that leverages its deep expertise in clinical development and collaboration with partners to efficiently bring promising therapies to market. They aim to make a significant impact on patient outcomes by discovering and developing transformative therapies.

   Company Address: 100 Washington Blvd Stamford 6902 CT
   Company Phone Number: 883-9490   Stock Exchange / Ticker: NASDAQ SWTX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Springworks Therapeutics Inc

Springworks Therapeutics Inc. Boasts $5.447 Million in Revenue Amidst Rising Net Losses

Springworks Therapeutics Inc is a biopharmaceutical company based in Stamford, Connecticut, specializing in the development of innovative treatments for severe rare diseases and various forms of cancer. The company recently announced its financial results for the most recent fiscal period, reporting a revenue of $5.447 million. However, the company also disclosed a net loss of $-325.104 million, which was higher than the net loss of $-220.571 million in the previous year.
Despite the significant net loss, Springworks Therapeutics remains optimistic about its future prospects. The company expects to generate revenue of $5.45 million in the fiscal period 2023, indicating a positive outlook for the coming year. Additionally, Springworks Therapeutics has managed to decrease its loss per share from $-5.21 to $-5.15 compared to the previous fiscal year.


SpringWorks Therapeutics Raises Over $316 Million to Fuel Innovations in Rare Disease and Cancer Treatments.

Published Fri, Dec 8 2023 9:05 PM UTC

SpringWorks Therapeutics Raises $316.25 Million in Successful Public Offering
STAMFORD, Conn., Dec. 08, 2023 - SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a leading biopharmaceutical company specializing in severe rare diseases and cancer treatments, proudly announced the successful closure of its underwritten public offering. This groundbreaking endeavor saw 10,905,1...


SpringWorks Therapeutics Propels Breakthroughs in Rare Diseases and Cancer through Successful Public Offering

Published Tue, Dec 5 2023 5:32 AM UTC

SpringWorks Therapeutics Announces Pricing and Details of Public Offering, Set to Raise Approximately $275 Million
In a recent press release, SpringWorks Therapeutics, a leading biopharmaceutical company focused on severe rare diseases and cancer, announced the pricing of its underwritten public offering. The offering consists of 9,482,758 shares of common stock at a pub...

Financing Agreement

SpringWorks Therapeutics Seeks Capital Boost with its Proposed Public Offering of Common Stock

Published Mon, Dec 4 2023 9:13 PM UTC

SpringWorks Therapeutics, a leading biopharmaceutical company focusing on severe rare diseases and cancer, has recently announced its plan to commence an underwritten public offering of $250.0 million worth of shares of its common stock. This move comes as the company aims to raise additional capital to support its ongoing research and development efforts.
The offering w...

Springworks Therapeutics Inc

Springworks Therapeutics Inc Delivers Impressive Q3 2023 Revenue, Mirroring Previous Year's Success

As the financial results for Springworks Therapeutics Inc are released for the time-frame ending September 30, 2023, investors may feel underwhelmed by the company's performance. However, it is crucial to analyze these figures in context to gain a deeper understanding of the company's overall stability.
First and foremost, the earnings per share (EPS) remained at $0.00 per share for this reporting period, which is the same as the previous year and the previous reporting season. While this may seem disappointing, it is important to note that Springworks Therapeutics Inc has managed to maintain this level, indicating stability and consistency.

  Company Estimates
  Revenue Outlook
Springworks Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Springworks Therapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com